Why Solbar Ningbo Protein Technology's (SHSE:603231) Shaky Earnings Are Just The Beginning Of Its Problems
Why Solbar Ningbo Protein Technology's (SHSE:603231) Shaky Earnings Are Just The Beginning Of Its Problems
Solbar Ningbo Protein Technology Co., Ltd.'s (SHSE:603231) recent weak earnings report didn't cause a big stock movement. We think that investors are worried about some weaknesses underlying the earnings.
Solbar 寧波蛋白科技有限公司's(上海證券交易所代碼:603231)最近疲軟的收益報告並未導致股市大幅波動。我們認爲,投資者擔心收益背後的一些弱點。
The Impact Of Unusual Items On Profit
不尋常物品對利潤的影響
To properly understand Solbar Ningbo Protein Technology's profit results, we need to consider the CN¥14m gain attributed to unusual items. We can't deny that higher profits generally leave us optimistic, but we'd prefer it if the profit were to be sustainable. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. Which is hardly surprising, given the name. If Solbar Ningbo Protein Technology doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.
爲了正確理解Solbar寧波蛋白科技的盈利業績,我們需要考慮歸因於不尋常項目的1400萬元人民幣的收益。我們不能否認更高的利潤通常會讓我們感到樂觀,但如果利潤是可持續的,我們更願意這樣做。當我們分析全球絕大多數上市公司時,我們發現重大不尋常的事項往往不會重演。考慮到這個名字,這並不奇怪。如果Solbar寧波蛋白科技沒有看到這種貢獻重演,那麼在其他條件相同的情況下,我們預計其本年度的利潤將下降。
Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Solbar Ningbo Protein Technology.
注意:我們始終建議投資者檢查資產負債表的實力。點擊此處查看我們對Solbar寧波蛋白科技的資產負債表分析。
Our Take On Solbar Ningbo Protein Technology's Profit Performance
我們對Solbar寧波蛋白科技盈利表現的看法
We'd posit that Solbar Ningbo Protein Technology's statutory earnings aren't a clean read on ongoing productivity, due to the large unusual item. Because of this, we think that it may be that Solbar Ningbo Protein Technology's statutory profits are better than its underlying earnings power. But at least holders can take some solace from the 16% per annum growth in EPS for the last three. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. In light of this, if you'd like to do more analysis on the company, it's vital to be informed of the risks involved. Every company has risks, and we've spotted 1 warning sign for Solbar Ningbo Protein Technology you should know about.
我們認爲,由於這個很大的不尋常項目,Solbar 寧波蛋白科技的法定收益並不能完全反映持續的生產力。因此,我們認爲可能是Solbar寧波蛋白科技的法定利潤要好於其基礎盈利能力。但是,至少持有人可以從過去三年的每股收益每年增長16%中得到一些安慰。歸根結底,如果你想正確地了解公司,必須考慮的不僅僅是上述因素。有鑑於此,如果你想對公司進行更多分析,了解所涉及的風險至關重要。每家公司都有風險,我們發現了一個你應該知道的Solbar寧波蛋白科技的警告信號。
Today we've zoomed in on a single data point to better understand the nature of Solbar Ningbo Protein Technology's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.
今天,我們放大了單個數據點,以更好地了解Solbar寧波蛋白科技的利潤性質。但是,如果你能夠將注意力集中在細節上,總會有更多的事情需要發現。有些人認爲高股本回報率是優質業務的好兆頭。因此,你可能希望看到這份擁有高股本回報率的公司的免費集合,或者這份內部所有權高的股票清單。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接聯繫我們。或者,也可以發送電子郵件至編輯團隊 (at) simplywallst.com。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。